Company news
Beijing Foyou Pharma Co., Ltd. Class A (SSE:601089) news
Beijing Foyou Pharma Co., Ltd. Class A news releases on 6ix. Latest, Sep 2, 2026: "BEIJING FOYOU PHARMA CO., LTD."Announcement on Pledge of Shares Held…
Press releases & updates
"BEIJING FOYOU PHARMA CO., LTD."Announcement on Pledge of Shares Held by Persons Acting in Concert with the Controlling Shareholder
September 1, 2026
"BEIJING FOYOU PHARMA CO., LTD."Announcement on Obtaining Drug Registration Certificate for Bromocriptine Mesylate Tablets
August 21, 2026
"BEIJING FOYOU PHARMA CO., LTD."Announcement on the Completion of Raised-Fund Investment Projects
August 14, 2026
"BEIJING FOYOU PHARMA CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing
August 11, 2026
"BEIJING FOYOU PHARMA CO., LTD."Announcement on Obtaining Drug Registration Certificate for Brexpiprazole Orally Disintegrating Tablets
August 7, 2026
"BEIJING FOYOU PHARMA CO., LTD."Announcement on the Proposed Selection in the 12th Batch of National Centralized Drug Procurement
August 3, 2026
"BEIJING FOYOU PHARMA CO., LTD."Announcement on Obtaining Notice of Approval for Drug Supplementary Application by Subsidiaries
July 16, 2026
"BEIJING FOYOU PHARMA CO., LTD."Announcement on the Change of Business License of a Controlled Subsidiary
July 13, 2026
"BEIJING FOYOU PHARMA CO., LTD."Announcement on Inclusion of Products of the Company and Its Subsidiaries in the "National Essential Medicines List (2026 Edition)"
July 10, 2026
"BEIJING FOYOU PHARMA CO.,LTD."Announcement on Obtaining the Drug Supplementary Application Approval Notice for Levothyroxine Sodium Tablets
July 1, 2026
Announcement on Approval Notice of the Supplementary Application for Drugs Obtained for Pinaverium Bromide Tablets
June 24, 2026
Announcement on Obtaining Drug Registration Certificate for Pimecrolimus Cream
June 16, 2026
Announcement on Obtaining Drug Registration Certificate for Methimazole Tablets
June 1, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 26, 2026
Announcement on Obtaining Drug Registration Certificate for Clopidogrel Aspirin Tablets
May 21, 2026
Announcement on Obtaining Drug Registration Certificate for Olmesartan Medoxomil Orally Disintegrating Tablets
May 7, 2026
Report for Q1 2026
April 24, 2026
Announcement on Obtaining Approval for Marketing of Chemical APIs
April 23, 2026
Announcement on Convening the Q1 2026 Performance Briefing
April 21, 2026
Announcement on Obtaining Drug Registration Certificate for Pioglitazone-Metformin Tablets (I)
April 20, 2026
Announcement on 2025 Annual Profit Distribution Plan
April 13, 2026
Announcement on Obtaining Drug Registration Certificate for Dibutyrosine Adenosyl Methyltransferase Enteric-coated Tablets
April 7, 2026
Announcement on Obtaining the Notice of Approval for Drug Clinical Trials of Bimatoprost Ointment
March 31, 2026
Announcement on Subsidiary's Passing GMP Compliance Inspection
March 30, 2026
Announcement on Obtainment of Drug Registration Certificate for Icosapent Ethyl Soft Capsules
March 23, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials
March 16, 2026
Announcement on Selection of Products for Continuation Procurement Under National Procurement Scheme After Agreement Expiry
February 11, 2026
Announcement on Obtaining Drug Registration Certificate for Bromhexine Hydrochloride Oral Solution
February 10, 2026
Announcement on Change of the Signing Accountant
January 29, 2026
Announcement on Obtaining Drug Registration Certificate for Trazodone Hydrochloride Tablets
January 23, 2026
Announcement on Change of Investor Contact Number
December 26, 2025
Announcement on Completion of Industrial and Commercial Filing
December 18, 2025
Announcement on Approval Notice for Clinical Trials of Ketoprofen Gel Patch
November 27, 2025
Announcement on the Election of Employee Directors and the Adjustment of Audit Committee Members
November 14, 2025
Announcement on Obtainment of the Drug Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets (I)
November 11, 2025
Announcement on Proposed Selection in the 11th National Centralized Drug Procurement
October 29, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 28, 2025
Announcement on Obtaining Drug Registration Certificate for Dydrogesterone Tablets
October 21, 2025
Announcement on Obtaining Drug Registration Certificate for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II)
September 29, 2025
Announcement on Obtaining Drug Registration Certificate for Pioglitazone-Metformin Tablets (15 mg/850 mg)
September 16, 2025
Announcement on Obtaining Drug Registration Certificate for Arotinolol Hydrochloride Tablets
September 8, 2025
Announcement on Obtaining Drug Registration Certificate for Amlodipine Besilate and Benazepril Hydrochloride Capsules
September 4, 2025
Announcement on Obtaining Drug Registration Certificate for Levothyroxine Sodium Tablets
August 26, 2025
Announcement on Resolutions of the 2nd Meeting of the 3rd Board of Supervisors
August 18, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 14, 2025
Announcement on Wholly-owned Subsidiary Changing Business License
August 13, 2025
Announcement on Abnormal Fluctuations in Stock Trading
August 4, 2025
Announcement on Obtaining Drug Registration Certificate for Lansoprazole Enteric Capsules
July 31, 2025
Announcement on Approval Notice of the Supplementary Application for Drugs Obtained by the Subsidiary
July 30, 2025
Announcement on Obtaining Drug Registration Certificate for Bifonazole Solution
July 29, 2025